- Summits
- Sponsorship
- News
- About
Blood collection is one of the most common procedures in healthcare. It happens billions of times every year across hospitals, diagnostic labs, and outpatient clinics. Yet the process itself has changed little over the decades. A Netherlands-based robotics company believes it can change that, and investors are paying attention.
Vitestro has raised $70 million in an oversubscribed Series B round to advance its autonomous robotic blood collection technology and prepare the company for broader clinical adoption. The round drew strategic backing from major healthcare players, including Labcorp Venture Fund, Mayo Clinic, and Sutter Health, along with financial investors such as InterVest, PGGM, Puma Venture Capital, and ROM Utrecht.
Existing investors, including Invest-NL, EIC Fund, NYBC Ventures, and Sonder Capital, also continued their support, alongside medtech pioneer Fred Moll.
The new funding will support further development of the company’s robotic blood collection system, regulatory progress in the United States, and preparation for wider commercial deployment.
Vitestro’s technology is centred on its Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™), designed to perform diagnostic blood draws with minimal human intervention.
The system combines robotics, multimodal imaging, and artificial intelligence to locate suitable veins, guide needle placement, and collect blood samples. The goal is to support phlebotomy teams by handling routine blood draws, particularly in high-volume outpatient settings where demand can place pressure on staff.
For Vitestro’s leadership, the financing marks an important step as the company moves from development into larger clinical use.
“Closing our Series B financing reflects strong conviction in our mission to establish a new standard in autonomous robotic venous access and diagnostic blood collection,” said Toon Overbeeke, Chief Executive Officer and co-founder of Vitestro. “Our technology has evolved from a novel vision into a clinically validated reality, and we are grateful for the support of this distinguished syndicate of strategic, healthcare, and life science investors as we move toward broad clinical adoption. Diagnostic blood collection remains the highest-volume invasive medical procedure globally, with billions of procedures performed annually.”
The company plans to use the funding to improve the platform’s technical capabilities, expand clinical studies and pilot programs, and grow its team as interest from healthcare providers increases.
Support from diagnostic and healthcare organisations highlights the interest in automating parts of clinical workflows that have traditionally relied entirely on manual procedures.
“The Labcorp Venture Fund sees strong potential in solutions that modernise core diagnostic processes and improve consistency for patients,” said Megann Vaughn Watters, Head of Labcorp Venture Fund. “Applying robotics, multimodal imaging and AI to clinically validated diagnostic blood collection is an exciting approach, and we’re thrilled to support Vitestro as they advance this important work.”
For veteran medtech entrepreneur Fred Moll, the technology addresses a long-standing gap in clinical innovation.
“Vitestro is redefining one of the largest and most under innovated clinical workflows with a first-of-its-kind autonomous robotic platform for diagnostic blood collection addressing an enormous unmet global market need,” he said. “I believe this technology has the potential to establish a new standard of care, much as robotic surgery did in its early days.”
Vitestro’s Aletta® system is already CE-marked and being deployed in clinical and pre-commercial environments in Europe. The company is also working toward regulatory clearance in the United States through the FDA’s De Novo pathway.
Alongside regulatory work, the company plans to expand manufacturing capacity and strengthen its commercial infrastructure in preparation for wider rollout.
As healthcare systems deal with staffing pressures and growing diagnostic demand, technologies that can automate routine clinical tasks are drawing increasing attention. For Vitestro, the next phase will be demonstrating how autonomous blood collection fits into everyday clinical workflows at scale.
Following the success of its Middle East flagship event, MedTech World is now heading to Florida for MedTech World North America, taking place in West Palm Beach from 11 to 13 May 2026.
The North America edition will convene global industry leaders, investors, and innovators for focused discussions, curated networking, and cross-border collaboration opportunities. If you are looking to be part of this milestone flagship event, you can engage in ways that align with your goals:
